Every 10-Q that Repligen (RGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGEN filings page.
Repligen Corporation reported Q2 2026 revenue of $204.1 million, up 11.9% from Q2 2025, and first-half revenue of $398.4 million, up 13.3%. Product growth was broad-based across filtration, chromatography, process analytics and proteins. Gross margin improved to 53.9% from 51.0%, driven by favorable product mix and better leverage on indirect labor and overhead.
Net income fell to $5.0 million in Q2 and $13.3 million year-to-date, reflecting a higher effective tax rate and a $13.7 million loss on the sale of Polymem S.A.S. Repligen ended June with $606.8 million in cash and equivalents plus $203.7 million in U.S. Treasury bills and generated $61.1 million of operating cash flow in the first half. The company is restructuring its manufacturing footprint, incurring $4.2 million of charges year-to-date and targeting completion by 2027. Subsequent to quarter-end, it agreed to acquire BioLife Solutions for approximately $1.5 billion, with BioLife stockholders to receive $11.25 in cash plus 0.1442 Repligen shares per BioLife share, subject to customary approvals and a planned closing in the fourth quarter of 2026.
Repligen Corporation reports solid growth for the three months ended March 31, 2026, with total revenue of $194,255 (amounts in thousands), up 14.8% from 2025. Product revenue rose across all major franchises, including filtration, chromatography, process analytics and proteins.
Net income increased to $8,333, or $0.15 per diluted share, despite a $13,763 loss on the sale of Polymem S.A.S., which was partly offset by a $6,561 income tax benefit. Gross margin improved to 55.7% as higher volumes and mix more than covered cost increases.
Repligen ended the quarter with cash and cash equivalents of $582,650 and marketable securities of $201,881, supporting total assets of $2,930,772 and $600,000 principal of 1.00% Convertible Senior Notes due 2028. The company also began new restructuring initiatives and continues to work on remediating previously identified material weaknesses in internal control over financial reporting.
Repligen Corporation reported Q3 2025 results with total revenue of $188.8 million and net income of $14.9 million, a turnaround from a $0.7 million loss a year ago. For the first nine months of 2025, revenue reached $540.3 million with net income of $35.6 million.
Cash and cash equivalents were $748.7 million, supporting a strong balance sheet with total assets of $2.92 billion. The company closed the 908 Devices bioprocessing analytics portfolio acquisition for $69.9 million in cash, recording provisional goodwill of $50.1 million and incurring $10.5 million in transaction and integration costs year to date. Contingent consideration fell to $7.6 million, producing gains of $4.1 million in Q3 and $12.1 million year to date.
The restructuring plan was completed in Q2 2025, with $4.1 million in related charges in the first nine months of 2025. The 1.00% Convertible Senior Notes due 2028 had a $537.9 million carrying amount and were not convertible for Q4 2025 under the indenture’s trading condition. Shares outstanding were 56,290,749 as of October 31, 2025.